Pain perception has evolved as a warning mechanism to alert organisms to tissue damage and dangerous environments 1,2 . In humans, however, undesirable, excessive or chronic pain is a common and major societal burden for which available medical treatments are currently suboptimal 3,4 . New therapeutic options have recently been derived from studies of individuals with congenital insensitivity to pain (CIP) 5,6 . Here we identified 10 different homozygous mutations in PRDM12 (encoding PRDI-BF1 and RIZ homology domaincontaining protein 12) in subjects with CIP from 11 families. Prdm proteins are a family of epigenetic regulators that control neural specification and neurogenesis 7,8 . We determined that Prdm12 is expressed in nociceptors and their progenitors and participates in the development of sensory neurons in Xenopus embryos. Moreover, CIP-associated mutants abrogate the histone-modifying potential associated with wild-type Prdm12. Prdm12 emerges as a key factor in the orchestration of sensory neurogenesis and may hold promise as a target for new pain therapeutics 9,10 .
Pain perception has evolved as a warning mechanism to alert organisms to tissue damage and dangerous environments 1,2 . In humans, however, undesirable, excessive or chronic pain is a common and major societal burden for which available medical treatments are currently suboptimal 3, 4 . New therapeutic options have recently been derived from studies of individuals with congenital insensitivity to pain (CIP) 5, 6 . Here we identified 10 different homozygous mutations in PRDM12 (encoding PRDI-BF1 and RIZ homology domaincontaining protein 12) in subjects with CIP from 11 families. Prdm proteins are a family of epigenetic regulators that control neural specification and neurogenesis 7, 8 . We determined that Prdm12 is expressed in nociceptors and their progenitors and participates in the development of sensory neurons in Xenopus embryos. Moreover, CIP-associated mutants abrogate the histone-modifying potential associated with wild-type Prdm12. Prdm12 emerges as a key factor in the orchestration of sensory neurogenesis and may hold promise as a target for new pain therapeutics 9,10 .
We studied two families whose pedigrees were consistent with autosomal recessive CIP. We excluded mutations in the known causative genes for CIP 11, 12 and for clinically similar types of hereditary sensory and autonomic neuropathy (HSAN; types IV and V) [13] [14] [15] . SNP array-based autozygosity mapping in a consanguineous family (family A) identified a single 11.5-Mb homozygous region on chromosome 9q33.2-34.13 (Fig. 1a) . As this large interval contained almost 150 genes (Supplementary Table 1) , we performed exome sequencing on the index patient of family A and the unrelated single CIP patient from family B. Although exome sequencing of the subject from family A yielded no obvious pathogenic variant in genes located in the autozygous region on chromosome 9, we observed a homozygous missense mutation in one of these positional candidate genes, PRDM12 (NM_021619.2), in the patient from family B (Fig. 1a and Supplementary Fig. 1 ). We then performed Sanger sequencing of PRDM12 for multiple individuals from family A and identified a homozygous trinucleotide expansion of alanine codons from 12 to 19 in the terminal exon in all affected subjects ( Fig. 1a and Supplementary Fig. 1 ). In an independent approach, we carried out exome sequencing on two individuals from two unrelated families with genetically unclassified CIP, family C and family D, and identified PRDM12 as the only gene that carried different biallelic missense mutations in both subjects ( Fig. 1b and Supplementary  Fig. 1 ). Subsequently, we screened PRDM12 in 158 individuals with autosomal recessive or isolated unexplained CIP or HSAN. We found seven additional unrelated index patients with homozygous PRDM12 mutations. The majority of the variants were missense mutations; however, affected individuals from one family (family J) had an 18-alanine repeat mutation, one isolated subject (family E) carried a frame-shift mutation and another isolated individual (family K) had an obligatory splice-site mutation ( Fig. 1c and Supplementary  Fig. 1 ). This study was approved by the National Research Ethics Service, NRES Committee East of England-Cambridge Central, the Munich University Medical Research Ethics Committee and the Medical University of Vienna Ethics Committee. Informed consent was obtained from all study subjects or their legal representatives.
Transcriptional regulator PRDM12 is essential for human pain perception PRDM12 is a five-exon gene encoding a single protein isoform of 367 amino acids containing a PR domain (related to the SET methyltransferase domain), three zinc fingers and a C-terminal polyalanine tract (Fig. 1c) . The observed point mutations were distributed throughout the gene, altered strictly conserved protein residues and were predicted to interfere with normal protein function ( Supplementary Fig. 2, Supplementary Table 2 and Supplementary Note). In all 11 families studied, the PRDM12 mutations segregated as expected for recessive disease alleles (Supplementary Fig. 1) . None of the point mutations was present in public SNP databases (1000 Genomes, Exome Variant Server and dbSNP138) or in the institutional exome data sets of Helmholtz Zentrum München and the Cambridge Biomedical Research Campus. These resources together allow for the interrogation of exome data from >20,000 individuals. We suspected that the trinucleotide expansions to 18 and 19 alanine codons in two of the families studied here would be deleterious, as other known recessive and X-linked polyalanine expansion diseases in humans manifest clinically when the number of repeats exceeds 15 (refs. 16,17) . We found that the length of PRDM12 polyalanine in the general l e t t e r s population is polymorphic, with a maximum of 14 alanines ( Fig. 1d and Supplementary Fig. 3 ). This confirms that the alleles observed in family A and family J are exceptional. The phenotype of the affected individuals in the 11 families with PRDM12 mutations was largely consistent: they had been unable to feel acute or inflammatory pain from birth and could not identify noxious heat or cold. Consequently, as infants and children these individuals sustained numerous painless mutilating lesions of the tongue, perioral tissues and fingers due to self-biting, as well as injuries resulting from repeated unnoticed traumatic episodes and burns (Fig. 2a, Supplementary Note and Supplementary Table 3) . Corneal reflexes were absent, which led to progressive corneal scarring. In severely affected individuals, recurrent infections of the skin and occasionally of bones and joints had led to bone deformities and neuropathic joints later in life. Notably, large-fiber sensory modalities (light touch, vibration and proprioception) were mostly normal. Sweating and tearing occurred but were substantially reduced with respect to unaffected family members. No other autonomic dysfunction was observed; the senses of smell and hearing were normal. In family J, the phenotype was milder than in the other families and consisted of facial scratching, diabetes-like foot ulcers, intact corneal reflexes and intact sweating and tearing. Heterozygote carriers were all asymptomatic and had normal pain perception. We studied nerve biopsies of CIP patients, done for diagnostic purposes several years before our study, to evaluate peripheral projections of nociceptive sensory neurons (small myelinated Aδ fibers, normally constituting 30% of nociceptors, and unmyelinated C fibers, normally constituting 70% of nociceptors 18 ). We observed a severe loss of Aδ fibers in the sural nerves of two patients, whereas large-caliber axons for other sensory modalities were largely unaltered (Fig. 2b) . Quantitative and qualitative changes in C fibers could not be reliably determined in the nerve biopsies, as no suitable samples for electron microscopy were available (ref. 19 and Supplementary Note). However, results from skin biopsies of two CIP patients suggested that at least the peripheral terminals of C fibers were affected. We observed a complete absence of nerve fibers crossing the basement membrane to innervate the epidermis (normally representing the terminals of nociceptors and thermoceptors 18 ), whereas the subepidermal neural plexus and autonomic innervation of sweat glands were reduced compared to what was observed in unaffected individuals but were morphologically grossly normal ( Fig. 2c and Supplementary Fig. 4) .
Our clinical and histological findings suggested that mutations in PRDM12 cause developmental defects in the sensory neurons that are destined to become nociceptors. Therefore, we explored 8 0 6 VOLUME 47 | NUMBER 7 | JULY 2015 Nature GeNetics l e t t e r s the expression of Prdm12 during embryogenesis and in human pain neurons generated from stem cells. In mice, expression of Prdm12 (NM_001123362) starts around embryonic day 9.0 (E9.0) in the neural folds, which give rise to neural crest cells (Fig. 3a) . The neural crest consists of a transient, multipotent, migratory cell population that develops into various tissues, including the sensory ganglia that contain nociceptor cell bodies 20 . Prdm12 is prominently expressed in sensory spinal ganglia (dorsal root ganglia (DRG)) but not in sympathetic ganglia during the time when sensory neurons emerge (E10.5-E13.5), mature and differentiate (E14.5-postnatal day 14) 21 ( Fig. 3b and Supplementary Fig. 5a ). In addition, we found that Prdm12 was expressed primarily by neurons rather than by satellite glial cells or Schwann cells in the DRG (Supplementary Fig. 5b ).
To assess PRDM12 expression during nociceptor development in humans, we differentiated inducible pluripotent stem cells (iPSCs) into nociceptor-like neurons 22, 23 . PRDM12 expression began to increase on day 7 commensurate with neural crest specification. Expression then increased by more than 1,000-fold and peaked at day 9 ( Fig. 3c) .
We examined the electrophysiological properties of these cells after neuronal maturation and confirmed recording of nociceptor-specific tetrodotoxin-resistant sodium current ( Supplementary Fig. 6a,b) . In addition, nociceptor-like neurons derived from human embryonic stem cells also showed robust induction of PRDM12 expression during differentiation (Supplementary Fig. 6c ). Furthermore, we did not find PRDM12 expression in human adult tissues, except in the DRG (Supplementary Fig. 7 ). Taken together, these findings are consistent with an essential function of Prdm12 during nociceptor neurogenesis (although we note that limited expression of Prdm12 has also been observed in mouse brain and in spinal cords of mice and zebrafish 8, 24 ). A role for Prdm12 in neural embryogenesis was further supported by a study of Xenopus Prdm12 morphants. Knockdown of the frog ortholog (NM_001079430.1) resulted in an irregular distribution of marker genes of cranial sensory placodes 25 at the late tailbud stage (stage 28; Fig. 3d ), whereas other cranial placodes seemed mostly normal (Supplementary Fig. 8 ), suggesting that Prdm12 is a universal regulator of sensory neurogenesis in vertebrates. We next investigated the consequences of CIP-associated mutations for PRDM12 protein function. PRDM12 is a nuclear protein with a diffuse, lace-like pattern. We found that missense mutations affected neither protein expression nor subcellular localization ( Supplementary Fig. 9a,b) . Conversely, the polyalanine expansion mutation resulted in reduced levels of overexpressed PRDM12 in transfected cells and caused discrete, concentrated foci to form in the nucleus and cytoplasm (Fig. 4a) . Expression levels of the polyalanine expansion mutant were recovered upon proteasome inhibition, suggesting that the expansion causes aggregation of PRDM12 and renders the protein less stable and more susceptible to proteolysis, 
Myc-Prdm12 and FLAG-G9a were expressed in COS-7 cells (Input) and immunoprecipitated using anti-Myc (IP: Myc). Bound G9a was normalized to amounts of Prdm12 in the immunoprecipitation (IP) fraction and G9a protein in the lysate. According to the structural model for the PRDM12 zinc finger domains, His289 (orange) is one of the residues (cyan) that coordinate the zinc ion. Prdm12∆ZF is an artificial mutant lacking zinc fingers. 30 . Histone modifications have emerged as critical epigenetic checkpoints during neurogenesis [31] [32] [33] [34] , and aberrant epigenetic mechanisms cause defects in neuronal development, as observed in other human diseases [35] [36] [37] [38] . Therefore, we next investigated the effect of PRDM12 mutations on H3K9me2 levels. Overexpression of wild-type Prdm12 robustly increased H3K9me2 in Xenopus neurulastage embryos, whereas the CIP-associated missense Prdm12 mutants did not demonstrate such an effect (Fig. 4b) . Also, both human and mouse wild-type Prdm12 strongly induced H3K9me2 in Xenopus embryos, although the mammalian orthologs and the frog protein differed by ~15% of their amino acids (Supplementary Fig. 10 ). This supports the hypothesis that PRDM12 missense mutations cause CIP by impairing histone methylation capacity. Mechanistically, we found that the p.His289Leu alteration significantly reduced binding to G9a, whereas the other mutants bound G9a normally ( Fig. 4c and Supplementary Fig. 9c ). The putative structure of PRDM12 implies that His289 is one of the residues coordinating the zinc ion of the second zinc finger (Fig. 4c) , which is required for G9a association 30 . The mechanism by which other Prdm12 mutants interfere with H3K9 dimethylation remains to be determined ( Supplementary  Fig. 9 ). Substitutions of Ile102 and Trp160, which are located in the core of the PR domain (Fig. 4d) , are likely to alter the domain's structure. Arg168 and Glu172 contribute to the surface of the PR domain. As PR domains represent protein-interaction modules [39] [40] [41] [42] , mutations affecting these residues may alter the protein-binding capability of PRDM12-PR. PRDM12 is essential for the sensing of pain in humans, as pathogenic mutations cause a congenital loss of pain perception. Our data imply that the pathological mechanism involves a loss of control of histone modification during critical points in nociceptor genesis, possibly via G9a or related factors 34 . Increasingly, pathophysiological mechanisms of chronic and neuropathic pain are being found to correlate with epigenetic changes in the peripheral and spinal cord nociceptive circuits 9, 10 . The histone-modifying activity of PRDM12 suggests a possible target for new methods of pain relief through reprogramming of the overactive nociceptors.
MetHoDs
Methods and any associated references are available in the online version of the paper. Skin biopsies. A punch skin biopsy was obtained from the lower leg of P11 (at age 18). The sample was fixed in 2% periodate-lysine-paraformaldehyde for 24 h at 4 °C, washed in phosphate buffer and stored in 15% sucrose with phosphate buffer for 48 h at 4 °C. A second skin biopsy was obtained from the lower lip of P7 (at age 13) during surgery for perioral injuries. The tissue specimen was fixed in Zamboni's solution for 4 h at 4 °C, washed in phosphate buffer and stored in 10% sucrose with phosphate buffer for 24 h at 4 °C. Skin samples were then embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek), frozen in liquid nitrogen, cut into 50-µm free-floating sections and processed for immunofluorescence microscopy as described 43 .
Nerve fibers were visualized using rabbit anti-PGP9. To assess myelinated fibers in the lip skin, we stained sections with rabbit anti-PGP9.5 and mouse anti-myelin basic protein (clone SMI-94, Abcam, ab24567) followed by Cy3-conjugated donkey anti-rabbit IgG and Alexa Fluor 488-conjugated donkey anti-mouse IgG. Images were taken using an LSM 700 microscope with a Plan-Apochromat objective (Carl Zeiss) at 40× and 63× magnification.
Sural nerve biopsies. Four individuals from different families (P3, P6, P10 and P11) had had diagnostic sural nerve biopsies several years before the current study took place. We were able to reevaluate microscopic images of biopsies from two subjects (P6, biopsied at age 25, and P10, biopsied at age 7). Micrographs of toluidine blue-stained semithin cross-sections of nerve biopsies were used for morphometric evaluation. Myelinated fibers were identified by the observers, and the myelin sheath of each intact fiber was traced manually. In the selection of areas for analysis, care was taken to avoid perineural spaces, blood vessels and fixation artifacts.
Linkage studies. Autozygosity mapping was performed on four individuals from family A. Genomic DNA samples were processed using Nsp1 250K SNP chips (Affymetrix), and then the allele calls were analyzed with EXCLUDEAR 44 . Only one homozygous region >1.5 cM was shared by all four individuals.
Whole-exome sequencing. We carried out targeted exome capture and sequencing of the index patient of family A (P3) and individuals P6 (family B), P7 (family C) and P8 (family D) using a Genome Analyzer HiSeq 2000 system (Illumina). For enrichment of exons and flanking intronic sequences, we used the SureSelect Human All Exon 50 Mb kit (Agilent). We performed 100-bp paired-end runs, which resulted in sequences of 6.4 (P3), 6.2 (P6), 8.2 (P7) and 12.3 (P8) Gb. The average read depths were 94 (P3), 93 (P6), 102 (P7) and 156 (P8), with 91% (P3), 89% (P6), 95% (P7) and 97% (P8) of the targeted regions covered at least 20-fold. Read alignment was performed with BWA (version 0.5.8) to the human genome assembly GRCh37/hg19. Singlenucleotide variants and small insertions and deletions were called with SAMtools. We excluded variants present in dbSNP132 with an average heterozygosity of >0.02 (P3, P6) or HapMap SNPs present in dbSNP135 with an average heterozygosity of >0.02 (P7, P8). We next filtered for variants found in any of 100 in-house controls (exomes from individuals with other diseases) or in the 1000 Genomes data (P3, P6) or for variants present in more than 8 of >4,000 in-house exomes from individuals with unrelated diseases (P7, P8). Variants were annotated with custom scripts, and we retained only potentially deleterious variants. Only genes containing biallelic variants were considered further.
Mutation detection in additional families. The PRDM12 coding region and splice sites were amplified using primers designed on the basis of the genomic sequence of PRDM12 (chr9: 133,539,981-133,558,384, GRCh37/hg19 assembly) and the PRDM12 mRNA NM_021619.2 sequence. The primer sequences and PCR conditions are available upon request. Amplicons were purified using NucleoFast PCR clean-up plates (Macherey-Nagel). Sequences of PCR products were determined using the ABI PRISM BigDye Terminator Ready Reaction Cycle Sequencing Kit (Applied Biosystems) and analyzed on an ABI PRISM 3730 DNA Analyzer (Applied Biosystems).
Protein-sequence analysis. We used PROVEAN 45 , SIFT 46 Table 2 ). We gathered sequences for homologs to human PRDM12 (NP_067632) by running PSI-BLAST with default settings against the NCBI nonredundant database. We created a multiple-sequence alignment using ClustalW with default settings (Supplementary Fig. 2 ).
Cloning of expression constructs. We generated the construct for wildtype human PRDM12 in a pcDNA3 vector by tagging commercially purchased PRDM12 template (Source BioScience) with an N-terminal HA epitope tag. Point mutations were introduced using the QuikChange II SiteDirected Mutagenesis Kit (Agilent). The polyalanine expansion mutations were obtained by overlap-extension PCR 50 . PRDM12 exon 5 harboring the expansion was amplified from patients' genomic DNA using the primers 5′-GCGGCTTCAACTCGCGCA-3′ and 5′-TCACAGCACCATGGCCGGC-3′. The remaining coding sequence of PRDM12 was amplified from the wild-type PRDM12 construct using the primers 5′-ATGATGGGCTCCGTGCTCC-3′ and 5′-TGCGCGAGTTGAAGCCGC-3′. Gel-purified products were used for recombinant PCR with both fragments as the template. The full-length products were introduced into the pCDNA3 vector with an N-terminal HA tag.
Myc-tagged mouse Prdm12 cDNA (NM_001123362) was generated from mRNA from mouse E13.5 whole embryos and inserted into EcoRI and NotI sites of the mammalian expression vector pCMV-Myc. Mutations were generated using overlap-extension PCR. Mutated sequences were inserted into EcoRI and NotI sites of pCMV-Myc. An expression plasmid for an artificial Prdm12 mutant lacking all three zinc finger motifs (Prdm12∆ZF) was provided by Yoichi Shinkai (RIKEN Institute, Saitama, Japan) and subcloned into pCMV-Myc.
Xenopus laevis Prdm12 cDNA (NM_001079430) was obtained from stage-22 embryos. Generation of an expression construct for Myc-tagged Xenopus Prdm12 in pCS2 vector is described elsewhere (S. Matsukawa et al., in preparation). Mutants of Xenopus Prdm12 were obtained by overlap-extension PCR and subcloned into EcoRI and XbaI sites of the pCS2 vector.
In situ hybridization of mouse embryos. Mouse embryos (C57BL/6J) were processed for whole-mount and section mRNA in situ hybridization with digoxigenin-labeled probes and signal detection with the chromophoric substrate nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; Roche) as described previously 8, 51 . The Prdm12 riboprobe was synthesized from linearized pGEM-T Easy plasmid vector containing a partial Prdm12 mRNA 8 .
RT-PCR analysis of mouse Prdm12. Tissues were collected from wild-type C57BL/6J mice. Dorsal root ganglia (DRG) were isolated when possible (developmental stages E12 and beyond), and whole embryos and neural tubes were used at earlier developmental stages. Sympathetic ganglia were dissected from E13.5 embryos. The mouse Schwann cell line MSC80 (a gift from Professor Roman Chrast, Karolinska Institutet, Stockholm, Sweden) was maintained at low passages and tested negative for mycoplasma. Identity of the cells was determined by detection of Schwann cell markers S100, Gfap, Egr2 and Mpz. DRG explants and DRG neurons were obtained and cultured as described previously 52, 53 . Total RNA was extracted from tissues and cell cultures using the RNeasy Mini Kit (Qiagen). Reverse transcription was performed with the PrimeScript RT Reagent Kit (Takara Bio) or Omniscript RT Kit (Qiagen). For PCR, we used a variety of primers and either GoTaq G2 DNA Polymerase (Promega) or Platinum Taq High-Fidelity Polymerase (Life Technologies). Amplicons were resolved on agarose gels, and DNA bands were imaged under UV light.
PRDM12 expression study in human adult tissues. Human adult tissue cDNA panels (Human MTC Panels I and II) were purchased from Clontech. PCR was performed using 100 ng of cDNA and Hot Star Master Mix (Qiagen). Amplicons were run and examined on agarose gels, and DNA bands were visualized under UV light.
hESC and iPSC sensory neuron differentiation. The human embryonic stem cell (hESC) line H9 was obtained from Pfizer (New York, USA), and the iPSC line Sendai F was generated by Neusentis Research Unit (Pfizer, Cambridge, UK). Cell lines were shown to express pluripotency markers by quantitative RT-PCR and confirmed to be mycoplasma free before being used for experiments, but they were not further authenticated. hESC and iPSC sensory neuron differentiation was performed as previously reported 22, 23 . Cells were seeded as single cells in mTeSR1 (StemCell Technologies) medium on Matrigel (BD Biosciences) 48 h before neural induction (day 0). KSR medium (390 ml Knockout DMEM, 100 ml Knockout Serum Replacement, 5 ml nonessential amino acids, 5 ml L-glutamine (all from Life Technologies), 3.5 ml β-mercaptoethanol) containing small-molecule inhibitors LDN193189 (1 µmol/l) and SB-431542 (10 µmol/l) was added to cells from day 0 to day 4 to drive anterior neuroectoderm specification. From day 3, CHIR99021 (3 µmol/l), DAPT (10 µmol/l) and SU5402 (10 µmol/l) were added to promote neural crest phenotypes. Cells were fed daily, and N2B27 medium (480 ml neurobasal medium, 5 ml N-2 supplement, 10 ml B-27 supplement, 5 ml L-glutamine (all from Life Technologies), 3.5 ml β-mercaptoethanol) was added in 25% increments every other day starting on day 4 (100% N2B27 medium on day 10). On day 11, maturation medium (N2B27 with human NGF-b BDNF, NT-3 and GDNF, all from Peprotech and used at 25 ng/ml final concentration) was added and used for long-term culture. Cultures were treated with mitomycin C to reduce the non-neuronal population.
Quantitative RT-PCR of hESC-and iPSC-derived sensory neurons. Total RNA was isolated using the RNeasy Mini Kit with on-column DNaseI treatment. Then cDNA was synthesized using a high-capacity RNA-to-cDNA kit (Applied Biosystems). Quantitative RT-PCR was performed using Taqman gene expression mastermix (Applied Biosystems) and customized TILDA cards containing Taqman primer probe sets (Life Technologies) on an ABI PRISM 7900HT machine (Applied Biosystems). Gene expression was analyzed, normalized to that of GAPDH and entered into line graphs or heat maps using Bioconductor packages (Life Technologies).
Electrophysiological recordings of iPSC-derived sensory neurons. All recordings were performed on fully differentiated iPSC-derived sensory neurons (6 weeks after the addition of growth factor) within 1-2 d of cellular dissociation. Patch-clamp recordings were made using a Multiclamp 700A amplifier (Molecular Devices) and digitized by a Digidata 2000 (Molecular Devices). Glass borosilicate pipettes (Science Products) were used with R pip of 2-4 MΩ resulting in R series < 10 MΩ. Whole-cell capacitances were fully compensated, and series resistance was compensated between 70% and 80%. Voltage-gated sodium channels were recorded in extracellular solution containing 140 mM NaCl, 4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES and 5 mM glucose; the pH was set at 7.4. Pipettes were filled with intracellular solutions containing 140 mM KCl, 1.6 mM MgCl 2 , 2.5 mM MgATP, 0.5 mM NaGTP, 2m M EGTA and 10 mM HEPES; the pH was set at 7.3. We elicited sodium currents by stepping the voltage from a holding potential of −120 mV to 0 mV for 100 ms. Functions of ion channels were further characterized by the application of tetrodotoxin.
Xenopus embryo manipulation. The developmental stages mentioned in this study correspond to the stages of normal Xenopus laevis development 54 . For the preparation of mRNAs for microinjections, pCS2 plasmid vectors containing wild-type and mutated Prdm12 cDNA were linearized and transcribed with the mMESSAGE mMACHINE SP6 transcription kit (Life Technologies). Morpholino antisense oligomers (MOs) were obtained from Gene Tools. The control MO and the Prdm12 MO had sequences 5′-CCTCTTACCTCAGTTA CAATTTATA-3′ and 5′-GCAGCACCGAGCCCATCATTAA TTC-3′, respectively. Embryos were obtained by artificial fertilization and dejellied with 4.6% L-cysteine hydrochloride at pH 7.8 during the one-cell stage. Synthesized mRNAs and MOs were microinjected with a Pico-Injector PLI-100 (Harvard Apparatus) into embryos at the two-cell stage. MO injection was lethal in 5% (control MO) and 20% (Prdm12 MO) of embryos.
To confirm the efficiency of the Prdm12 MO, we co-injected embryos with Myc-Prdm12 mRNA (1 ng/embryo) and control or Prdm12 MO (5, 10 and 20 ng/embryo). Protein extracts were prepared in RIPA buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 25 mM Tris-HCl, pH 7.4) at stage 26. Proteins were separated by SDS-PAGE, blotted onto Hybond-C membranes (GE Healthcare) and visualized using mouse anti-Myc (clone 9E10, Santa Cruz, sc-40) and mouse anti-α-tubulin (clone DM1A, SigmaAldrich, T9026) followed by HRP-conjugated goat anti-mouse IgG (Thermo Fisher, PI32230). Signals were obtained using Luminata Forte Western substrate (Millipore). For assessment of the distribution pattern of cranial placode markers, embryos were injected with 20 ng control or Prdm12 MO per embryo.
Whole-mount in situ hybridization of Xenopus embryos. For preparation of riboprobes for Prdm12 and cranial placode markers, pBluescript-SK-Prdm12, pCS2p-Islet1, pBluescript-SK-Ebf3, pBluescript-SK-Ath3, pGEM-Pax6, pBluescript-SK-Six3 and pCS2-Pax8 were linearized and used as templates. Probes were synthesized with T7 RNA polymerase and labeled with digoxigenin using the DIG RNA labeling kit (Roche). Whole-mount in situ hybridization was performed at the late tailbud stage (stage 26 or stage 28) with a modified Harland's protocol 55 using NBT/BCIP as the chromophoric substrate. The distribution pattern of markers was determined by visual inspection; for MO-injected embryos, patterns were categorized into three main types (at least 40 live embryos per condition).
Histone methylation studies. Wnt8, Chrd (for inducing neural crest-like cells 56 ; each 0.05 ng/embryo) and Prdm12 (wild type and CIP-associated mutations, 1 ng/embryo) mRNAs were co-injected. The ectoderm region (animal cap) of the injected embryos was dissected at the blastula stage and cultured until the mid-neurula stage (stage 15). Cell lysates were prepared in RIPA buffer, and proteins were resolved by SDS-PAGE. Immunoblotting was done using transfer to Hybond-C membranes and incubation with mouse anti-Myc (clone 9E10, Santa Cruz, sc-40), mouse anti-H3K9me2 (clone RR202, Millipore, 05-685) and rabbit anti-H3 (Millipore, 07-690) followed by HRP-conjugated goat anti-mouse IgG and HRP-conjugated goat anti-rabbit IgG (Thermo Fisher, PI32260). Signals were obtained using Luminata Forte Western HRP substrate (Millipore).
Expression levels of exogenous Prdm12. COS-7 cells were purchased from Sigma-Aldrich and maintained at low passages. The cell line tested negative for mycoplasma but was not further authenticated. Cells were cultured in DMEM containing 10% fetal bovine serum and 2 mM L-glutamine (Life Technologies). JetPei Transfection Reagent (Peqlab) was used to co-transfect cells with human (HA-tagged) and mouse (Myc-tagged) Prdm12 expression constructs and a GFP plasmid (control for transfection efficiency). Cells were lysed in lysis buffer (1% SDS, 10 mM Tris, pH 7.4) or RIPA buffer 24 h after transfection. The pellet remaining after extraction with RIPA buffer was sonicated and resuspended in RIPA buffer. To explore a potential effect of proteasomal degradation on Prdm12 turnover, we treated cells with 5 µM MG132. Proteins were resolved by SDS-PAGE and blotted onto Protran membranes (GE Healthcare).
